The level of cytokines in tears as a novel indicator of demyelinating diseases DOI
Jowita Adamczyk-Zostawa, Adam Wylęgała, Martyna Lis

et al.

Neurological Research, Journal Year: 2024, Volume and Issue: 46(6), P. 487 - 494

Published: April 11, 2024

A novel research objective is to identify new molecules in more readily accessible biological fluids that could be used the diagnosis of multiple sclerosis (MS) and other demyelinating disorders.

Language: Английский

Dry eye disease caused by viral infection: Past, present and future DOI Creative Commons
Min Wu,

Cuilian Sun,

Qin Shi

et al.

Virulence, Journal Year: 2023, Volume and Issue: 15(1)

Published: Dec. 4, 2023

Following viral infection, the innate immune system senses products, such as nucleic acids, to activate defence pathways, leading inflammation and apoptosis, control of cell proliferation, consequently, threat whole body. The ocular surface is exposed external environment extremely vulnerable infection. Several studies have revealed that infection can induce reduce tear secretion lacrimal gland (LG), consequently triggering morphological functional changes resulting in dry eye disease (DED). Understanding mechanisms DED caused by its potential therapeutic strategies are crucial for clinical interventional advances DED. This review summarizes roles pathogenesis DED, applicable diagnostic strategies, regions future studies.

Language: Английский

Citations

3
Epigenetic mechanisms of non-retinal components of the aging eye and novel therapeutic strategies DOI
Mónica Lamas

Experimental Eye Research, Journal Year: 2023, Volume and Issue: 236, P. 109673 - 109673

Published: Oct. 5, 2023

Language: Английский

Citations

2
Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials DOI Creative Commons
Lisa M. Nijm, Dagny Zhu, Mandy Hemphill

et al.

Ophthalmology and Therapy, Journal Year: 2022, Volume and Issue: 12(1), P. 355 - 364

Published: Nov. 18, 2022

This study sought to compare the efficacy of OC-01 (varenicline solution) nasal spray for treatment dry eye disease (DED) in postmenopausal women (PM+) versus who were not (PM-).This was a post hoc subgroup analysis data integrated from two prior randomized controlled clinical trials, ONSET-1 and ONSET-2. Women with 0.03 mg or vehicle control (VC) whose self-reported menopausal status (PM+ PM-) known included. Outcomes included difference (the [varenicline solution] change baseline [CFB] minus VC CFB) Schirmer test score (STS, mm) anesthesia dryness (EDS) measured on 100-mm visual analog scale (0 = no discomfort, 100 maximal discomfort). Least-squares mean differences derived covariance (ANCOVA) models.Overall, 449 female participants ONSET-2 trials groups this analysis. The treatment-menopausal interaction terms STS EDS ANCOVA logistic regression models statistically significant (p > 0.05), indicating consistency effect between PM- PM+ groups. similar (6.7 5.5 mm, respectively). (- - 4.1, respectively).OC-01 demonstrated promoting natural tear production improving symptoms both As menopausal-related hormonal changes may be associated more severe DED, these results support as an effective DED regardless presenting status.Post (ClinicalTrials.gov identifier NCT03636061) NCT04036292).

Language: Английский

Citations

3
Efficacy of the combination of cyclosporine and sodium hyaluronate eye drops on dry eye syndrome DOI Creative Commons
Lei Shen,

Nana Zhao,

Xue Wang

et al.

Tropical Journal of Pharmaceutical Research, Journal Year: 2024, Volume and Issue: 23(1), P. 117 - 124

Published: Feb. 5, 2024

Purpose: To investigate the efficacy and adverse effect of cyclosporine combined with sodiumhyaluronate (SH) eye drops on dry syndrome (DES).Methods: 148 patients DES treated in Nanjing Drum Tower Hospital Group Suqian Hospital,Jiangsu Province, China between January 2022 February 2023 were randomly assigned to control(70 cases) study groups (78 cases). Control group was SH drop (1 each onboth eyes 5 - 6 times a day, for 2 months), while both (the samedosage use control group) eyes, 4 6times two months). Tear film stability indices such as schirmer I test (SIT), tear break-up time(BUT) corneal fluorescein stain (FL) analyzed before after therapy.Results: There no significant difference BUT, SIT FL score beforetreatment. Compared treatment, BUT increased significantly (p < 0.05), FLscore dropped treatment 0.05). After groupshowed higher levels, lower than <0.05).Conclusion: The combination is effective treating DES.This regimen protects stability, effectively alleviates symptoms, improvesocular surface meibomian gland function, also increases lacrimal river height, withoutincreasing reactions. Further studies will be required, provide more evidence clinicalapplication this regimen.

Language: Английский

Citations

0
The level of cytokines in tears as a novel indicator of demyelinating diseases DOI
Jowita Adamczyk-Zostawa, Adam Wylęgała, Martyna Lis

et al.

Neurological Research, Journal Year: 2024, Volume and Issue: 46(6), P. 487 - 494

Published: April 11, 2024

A novel research objective is to identify new molecules in more readily accessible biological fluids that could be used the diagnosis of multiple sclerosis (MS) and other demyelinating disorders.

Language: Английский

Citations

0